超声微泡造影剂在冠状动脉粥样硬化性心脏病治疗中的应用进展  

Application progress of ultrasound microbubble contrast agent in treatment of coronary heart disease

作　　者：刘兴钊[1] 任建丽[1] 王志刚[1] 

机构地区：[1]重庆医科大学超声影像研究所,重庆市400010

出　　处：《临床超声医学杂志》2012年第7期471-473,共3页Journal of Clinical Ultrasound in Medicine

基　　金：国家自然科学基金青年科学基金项目(81000621);教育部博士点(新教师类)基金项目(20105503120008)

摘　　要：冠状动脉粥样硬化性心脏病(CHD)是威胁人类健康和生命的疾病之一,药物、介入及外科治疗均不能根治。外源性给予某些促血管生成因子或治疗基因能促进缺血心肌血管再生和侧支循环建立,改善心肌缺血。超声微泡造影剂作为促血管生成因子或治疗基因的载体,联合超声辐照能更安全、高效、靶向地导入缺血心肌组织,为CHD的治疗开辟了一个新的应用前景。本文就近年来超声微泡造影剂在CHD治疗中的应用进展做一综述。Coronary heart disease is one of the diseases threatening people＇s health and life,drug ,interventional and surgical treatment can not eradicate it. Some exogenous angiogenie factors or therapy gene can promote angiogenesis and the establishment of collateral circulation in ischemic myocardium and improve the situation of myocardial ischemia. Ultrasound microbubble contrast agent as the delivery of these angiogenic factors or therapy genes, can be more safely, efficiently and targeted transfer into ischemic myocardium combined with ultrasound irradiation. This opens up a new prospect for the treatment of coronary heart disease. This article reviews the application progress of ultrasound mierobubble contrast agent for coronary heart disease therapy in recent years.

关 键 词：治疗性血管生成 超声检查 造影剂 微泡 基因治疗 冠状动脉粥样硬化 

分 类 号：R541.4[医药卫生—心血管疾病] R445.1[医药卫生—内科学]